MA55200A - Composés utiles dans la thérapie du vih - Google Patents

Composés utiles dans la thérapie du vih

Info

Publication number
MA55200A
MA55200A MA055200A MA55200A MA55200A MA 55200 A MA55200 A MA 55200A MA 055200 A MA055200 A MA 055200A MA 55200 A MA55200 A MA 55200A MA 55200 A MA55200 A MA 55200A
Authority
MA
Morocco
Prior art keywords
useful compounds
hiv therapy
hiv
therapy
compounds
Prior art date
Application number
MA055200A
Other languages
English (en)
French (fr)
Inventor
La Rosa Martha Alicia De
John F Miller
B Narasimhulu Naidu
Vicente Samano
David Temelkoff
Emile Johann Velthuisen
Original Assignee
Glaxosmithkline Ip No 2 Ltd
Viiv Healthcare Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=69845479&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA55200(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxosmithkline Ip No 2 Ltd, Viiv Healthcare Co filed Critical Glaxosmithkline Ip No 2 Ltd
Publication of MA55200A publication Critical patent/MA55200A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/173—Purine radicals with 2-deoxyribosyl as the saccharide radical

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • AIDS & HIV (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
MA055200A 2019-03-06 2020-03-04 Composés utiles dans la thérapie du vih MA55200A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962814316P 2019-03-06 2019-03-06

Publications (1)

Publication Number Publication Date
MA55200A true MA55200A (fr) 2022-01-12

Family

ID=69845479

Family Applications (1)

Application Number Title Priority Date Filing Date
MA055200A MA55200A (fr) 2019-03-06 2020-03-04 Composés utiles dans la thérapie du vih

Country Status (22)

Country Link
US (4) US12240853B2 (https=)
EP (1) EP3934760A1 (https=)
JP (1) JP2022525013A (https=)
KR (1) KR20210136052A (https=)
CN (1) CN113811360A (https=)
AR (1) AR118240A1 (https=)
AU (1) AU2020231934B2 (https=)
BR (1) BR112021017604A2 (https=)
CA (1) CA3132112A1 (https=)
CL (1) CL2021002309A1 (https=)
CO (1) CO2021012579A2 (https=)
CR (1) CR20210460A (https=)
EA (1) EA202192433A1 (https=)
IL (1) IL285894A (https=)
MA (1) MA55200A (https=)
MX (1) MX2021010700A (https=)
PE (1) PE20212089A1 (https=)
PH (1) PH12021500034A1 (https=)
SG (1) SG11202109253SA (https=)
TW (1) TW202102233A (https=)
WO (1) WO2020178767A1 (https=)
ZA (1) ZA202106096B (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021021717A1 (en) 2019-07-27 2021-02-04 Brii Biosciences, Inc. Adenosine derivative and pharmaceutical composition comprising the same
PE20221037A1 (es) 2019-09-11 2022-06-17 Scripps Research Inst Profarmacos antivirales y composiciones farmaceuticas de los mismos
UY38982A (es) 2019-12-09 2021-06-30 Viiv Healthcare Co Composiciones farmacéuticas
WO2025068743A1 (en) 2023-09-27 2025-04-03 ViiV Healthcare UK (No.3) Limited Pharmaceutical composition of cabotegravir
US11718637B2 (en) * 2020-03-20 2023-08-08 Gilead Sciences, Inc. Prodrugs of 4′-C-substituted-2-halo-2′- deoxyadenosine nucleosides and methods of making and using the same
JP2024503755A (ja) * 2020-12-30 2024-01-26 サウザン・ユニバーシティ・オブ・サイエンス・アンド・テクノロジー ウイルス感染症治療用ヌクレオシド系化合物及びその用途
CN116710465A (zh) 2021-01-25 2023-09-05 腾盛博药生物科技有限公司 腺苷衍生物和包含其的药物组合物
TW202237146A (zh) * 2021-01-25 2022-10-01 美商布里生物科學股份有限公司 使用腺苷衍生物及衣殼抑制劑之hiv組合療法
JP2024507550A (ja) * 2021-02-23 2024-02-20 ヴィーブ、ヘルスケア、カンパニー Ｈｉｖ療法に有用な化合物
CN120958007A (zh) * 2023-01-30 2025-11-14 默沙东有限责任公司 4'-取代核苷逆转录酶抑制剂的前药
CN121909019A (zh) 2023-09-27 2026-04-21 Viiv保健英国第三有限公司 药物组合物

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB427857A (en) 1934-08-02 1935-05-01 Newsum Sons & Company Ltd H A new or improved system of construction for skeleton structures, particularly vehicle body frames and door frames
US4107288A (en) 1974-09-18 1978-08-15 Pharmaceutical Society Of Victoria Injectable compositions, nanoparticles useful therein, and process of manufacturing same
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
ATE250623T1 (de) 1999-05-12 2003-10-15 Yamasa Corp 4'-c-ethynyl-purin-nukleoside
EP1378509A4 (en) 2001-03-19 2009-03-25 Ono Pharmaceutical Co DRUGS WITH TRIAZASPIRO ç5.5] UNDECANDERIVATES AS ACTIVE SUBSTANCE
US7037718B2 (en) 2001-10-26 2006-05-02 Cornell Research Foundation, Inc. Mutant purine nucleoside phosphorylase proteins and cellular delivery thereof
CA2502109C (en) 2004-03-24 2010-02-23 Yamasa Corporation 4'-c-substituted-2-haloadenosine derivative
CN100532388C (zh) 2007-07-16 2009-08-26 郑州大学 2’-氟-4’-取代-核苷类似物、其制备方法及应用
US20090318380A1 (en) 2007-11-20 2009-12-24 Pharmasset, Inc. 2',4'-substituted nucleosides as antiviral agents
US8927513B2 (en) 2009-07-07 2015-01-06 Alnylam Pharmaceuticals, Inc. 5′ phosphate mimics
US9198972B2 (en) 2010-01-28 2015-12-01 Alnylam Pharmaceuticals, Inc. Monomers and oligonucleotides comprising cycloaddition adduct(s)
WO2011133871A2 (en) 2010-04-22 2011-10-27 Alnylam Pharmaceuticals, Inc. 5'-end derivatives
EP2619215B1 (en) 2010-09-22 2018-09-05 Alios Biopharma, Inc. Azido nucleosides and nucleotide analogs
US9770035B2 (en) 2011-10-06 2017-09-26 Dow Agrosciences Llc Nucleic acid molecules that target RPA70 and confer resistance to coleopteran pests
AU2013235220C1 (en) 2011-12-22 2019-03-28 Janssen Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
UA117095C2 (uk) 2011-12-22 2018-06-25 Аліос Біофарма, Інк. Нуклеозидна сполука або її фармацевтично прийнятна сіль
US9441007B2 (en) 2012-03-21 2016-09-13 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
HK1224229A1 (zh) 2013-06-26 2017-08-18 Alios Biopharma, Inc. 取代的核苷，核苷酸及其类似物
EP3055319A4 (en) 2013-10-11 2018-01-10 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
WO2015143712A1 (en) 2014-03-28 2015-10-01 Merck Sharp & Dohme Corp. 4'-substituted nucleoside reverse transcriptase inhibitors
TN2016000566A1 (en) 2014-06-24 2018-04-04 Alios Biopharma Inc Substituted nucleosides, nucleotides and analogs thereof
LT3160476T (lt) 2014-06-24 2021-04-12 Janssen Biopharma, Inc. Pakeistieji nukleozidai, nukleotidai ir jų analogai, skirti naudoti virusinių infekcijų gydyme
WO2016057866A1 (en) 2014-10-09 2016-04-14 Board Of Regents Of The University Of Nebraska Compositions and methods for the delivery of therapeutics
WO2016066283A1 (en) * 2014-10-31 2016-05-06 Sandoz Ag Improved fluorination process
MA41213A (fr) 2014-12-19 2017-10-24 Alios Biopharma Inc Nucléosides substitués, nucléotides et analogues de ceux-ci
CN108289931B (zh) * 2015-09-23 2022-10-11 默沙东公司 4’-取代的核苷逆转录酶抑制剂及其制备
JOP20170038B1 (ar) 2016-02-12 2021-08-17 Merck Sharp & Dohme مركبات للاستخدام لعلاج عدوى بفيروس hiv والوقاية منه
EP4299133A3 (en) 2016-06-23 2024-03-13 VIIV Healthcare Company Compositions and methods for the delivery of therapeutics
EP3529254B1 (en) 2016-11-03 2023-02-22 Laurence I. Wu Prodrugs of clofarabine
US20190185508A1 (en) 2017-12-15 2019-06-20 Merck Sharp & Dohme Corp. Deuterated nucleoside reverse transcriptase inhibitors
US20200407393A1 (en) * 2018-03-07 2020-12-31 Glaxosmithkline Intellectual Property (No. 2) Limited Medical Use
WO2019199667A2 (en) 2018-04-09 2019-10-17 Keaney Gregg F Certain pladienolide compounds and methods of use
WO2020031131A1 (en) 2018-08-09 2020-02-13 Glaxosmithkline Intellectual Property (No.2) Limited Compounds useful in hiv therapy
JP2021536444A (ja) 2018-08-30 2021-12-27 グラクソスミスクライン、インテレクチュアル、プロパティー、(ナンバー2)、リミテッドGlaxosmithkline Intellectual Property (No.2) Limited Ｈｉｖ療法に有用な化合物
ES2971482T3 (es) 2019-03-06 2024-06-05 Greentech Global Pte Ltd Dispersiones líquidas para haluros de acilo

Also Published As

Publication number Publication date
AU2020231934B2 (en) 2023-04-20
CO2021012579A2 (es) 2021-10-20
MX2021010700A (es) 2021-10-01
WO2020178767A1 (en) 2020-09-10
EP3934760A1 (en) 2022-01-12
CA3132112A1 (en) 2020-09-10
AU2020231934A8 (en) 2022-03-24
AU2020231934A1 (en) 2021-09-23
US20260035371A1 (en) 2026-02-05
IL285894A (en) 2021-10-31
ZA202106096B (en) 2023-03-29
CR20210460A (es) 2022-02-03
CN113811360A (zh) 2021-12-17
EA202192433A1 (ru) 2021-12-28
KR20210136052A (ko) 2021-11-16
CL2021002309A1 (es) 2022-09-20
AR118240A1 (es) 2021-09-22
PE20212089A1 (es) 2021-11-04
US20230174534A1 (en) 2023-06-08
US12240853B2 (en) 2025-03-04
US20220411425A1 (en) 2022-12-29
TW202102233A (zh) 2021-01-16
US20240182473A1 (en) 2024-06-06
JP2022525013A (ja) 2022-05-11
BR112021017604A2 (pt) 2021-11-16
SG11202109253SA (en) 2021-09-29
PH12021500034A1 (en) 2022-06-06

Similar Documents

Publication Publication Date Title
MA55200A (fr) Composés utiles dans la thérapie du vih
MA53280A (fr) Composés utiles dans la thérapie du vih
EP4045442A4 (en) VISION-ASSISTED ROBOTIC DEPALLETIZER
IL285771A (en) Therapeutic uses of relacorilant, a heteroaryl-ketone fused azadecalin glucocorticoid receptor modulator
EP3915928A4 (en) CRANE
EP3989959A4 (en) TRANSDERMAL FORMULATIONS
EP4043002A4 (en) Dental composition
EP3359100A4 (en) USE OF A STERILE SLEEVE IN THE MANUFACTURE OF SURGICAL SLUSH
EP3849570A4 (en) Blood plasma-containing compositions
EP4032455A4 (en) Cleaner
EP3952625A4 (en) CONVERTER
EP4049824C0 (en) MOLD
EP4029491A4 (en) Dental polymerizable composition
EP4037681C0 (en) CHEWABLE GEL DOSAGE FORM
EP3980440A4 (en) Anti-inflammatory agents
EP3960060A4 (en) CLEANING DEVICE
EP3941217A4 (en) THICKENING COMPOSITION
EP3924140C0 (en) WEIGHT BALANCING GANTRY
DK3722239T3 (da) Elevator
IL288237A (en) Combination therapy
EP4029490A4 (en) Polymerizable dental composition
EP3949952A4 (en) MEDICAL COMPOSITION
EP3792212A4 (en) Lift
EP4061375A4 (en) REMEDIES AGAINST MALARIA
PL3996650T3 (pl) Wanna